| T0844 |
Sulfamethoxypyridazine
|
80-35-3
|
98%
|
|
|
Sulfamethoxypyridazine (CL 13494) is a sulfanilamide antibacterial agent.
|
| T40111L |
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride
|
2691796-83-3
|
98%
|
|
|
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride is a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (P...
|
| T77635 |
LSD1-IN-27
|
2904571-94-2
|
98%
|
|
|
LSD1-IN-27 is a potent LSD1 inhibitor with an IC50 value of 13 nM.LSD1-IN-27 inhibited the stemness and migration of gastric cancer cells.LSD1-IN-27 inhibited th...
|
| T9616 |
PD-1/PD-L1-IN-10
|
2487550-41-2
|
98%
|
|
|
PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy.
|
| T38369 |
CAY10678
|
1268709-57-4
|
98%
|
|
|
CAY10678 is an mPGES-1 inhibitor that inhibits PD-1.CAY10678 reduces collagen deposition and T-cell depletion, and may be used to study melanoma.CASHIPS
|
| T77433 |
Feladilimab
|
2252518-85-5
|
98%
|
Feladilimab
|
|
Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist. Feladilimab binds to ICOS-expressing T cells, induces IFNγ, and increases PD-1/L...
|
| T11126 |
Durvalumab
|
1428935-60-7
|
98%
|
|
|
Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and ...
|
| T77075 |
Spartalizumab
|
1935694-88-4
|
98%
|
Spartalizumab
|
|
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that selectively binds to PD-1 at low concentrations and shows high activity. Spartali...
|
| T83970 |
IMMH 010 maleate
|
2541982-47-0
|
98%
|
|
|
IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological...
|
| T35394 |
Sintilimab (anti-PD-1)
|
2072873-06-2
|
95%
|
Sintilimab (anti-PD-1)
|
|
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding ...
|
| TP1076L |
AUNP-12 acetate
|
|
95.07%
|
|
|
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition t...
|
| T9902 |
Atezolizumab
|
1380723-44-3
|
95.10%
|
|
|
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD...
|
| T9359 |
PDL-1 cpd 10
|
2767424-13-3
|
98%
|
|
|
PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
|
| T9907 |
Nivolumab
|
946414-94-4
|
98%
|
|
|
Nivolumab (anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell...
|
| T4696 |
BMS202 hydrochloride (1675203-84-5(free base))
|
2089334-95-0
|
98%
|
|
|
BMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophys...
|
| T78269 |
Anti-Mouse PD-1 Antibody (RMP1-14)
|
|
98.01%
|
Anti-Mouse PD-1 Antibody (RMP1-14)
|
|
RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.
|
| T36899 |
INCB086550
|
2230911-59-6
|
98.21%
|
|
|
INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.
|
| T3146 |
BMS-202
|
1675203-84-5
|
98.24%
|
|
|
BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction.
|
| T9903 |
Avelumab
|
1537032-82-8
|
98.30%
|
|
|
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.
|
| T12379 |
PD-1-IN-22
|
2349372-98-9
|
98.64%
|
|
|
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor(IC50 of 92.3 nM).
|
